LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease
Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3148-3150
DOI: 10.1016/j.cgh.2026.01.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Katrine Thorhauge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark; Faculty of Health Sciences, In…. Hauptthemen laut MEDLINE: Mass Screening, Fatty Liver, Liver Cirrhosis. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Horizon 2020 Framework Programme, Novo Nordisk Fonden, Novo Nordisk A/S.
Abstract (Originalsprache)
Targeted screening for steatotic liver disease (SLD) is cost-effective and encourages lifestyle changes.1-3 The European Association for the Study of the Liver (EASL) recommends screening adults at risk of SLD to enable timely diagnosis and prevention, especially with emerging treatments like resmetirom and semaglutide.4 EASL guidelines suggest the fibrosis-4 index (FIB-4) as the first-line noninvasive test to identify candidates for secondary care referral with more accurate, resource-intensive assessments like liver stiffness measurements by transient elastography (TE).4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark; Faculty of Health Sciences, Institute of Clinical Research, University of Southern Denmark, Odense,…
- Evido Health, Copenhagen, Denmark. Electronic address: katrine@evido.health.
Förderung
- Horizon 2020 Framework Programme
- Novo Nordisk Fonden
- Novo Nordisk A/S
Zitieren
APA
Thorhauge, K., Lindvig, K., Schnefeld, H., Bech, K. T., Thiele, M., & Krag, A. (2026). LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease. Clinical Gastroenterology and Hepatology, 24(11), 3148-3150. https://doi.org/10.1016/j.cgh.2026.01.024
Vancouver
Thorhauge K, Lindvig K, Schnefeld H, Bech KT, Thiele M, Krag A. LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026;24(11):3148-3150. doi:10.1016/j.cgh.2026.01.024
BibTeX
@article{Thorhauge2026,
author = {Thorhauge, Katrine and Lindvig, Katrine and Schnefeld, Helle and Bech, Katrine Tholstrup and Thiele, Maja and Krag, Aleksander},
title = {LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {11},
pages = {3148--3150},
doi = {10.1016/j.cgh.2026.01.024}
}
EUVIMED